Literature DB >> 7640454

Characterization of cell surface antigens expressed in the HMA-1 breast cancer cell line.

N Ohuchi1, Y Harada, T Masuko, S Matano, S Mori.   

Abstract

This report describes the characterization of an estrogen receptor-positive breast cancer cell line, HMA-1, established from a breast cancer patient, based on the expression of tumor-associated antigens (TAAs), the HLA-DR antigen, and the c-erbB-2 proto-oncogene product. In flow cytometric and immunohistochemical analyses, HMA-1 was found to express increased levels of several TAAs including MUC1, TAG-72 (sialyl Tn), Tn, T, sialyl Le(a), Le(x), and Le(y). HMA-1 also expressed enhanced levels of the HLA-DR antigen and c-erbB-2 protein. These results indicate that HMA-1 is a unique cell line with abundant TAAs which may serve as an appropriate breast cancer cell line for application in the multidisciplinary research of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640454     DOI: 10.1007/bf00311535

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  31 in total

1.  Molecular characterization of a mucin-type antigen associated with human pancreatic cancer. The DU-PAN-2 antigen.

Authors:  M S Lan; A Khorrami; B Kaufman; R S Metzgar
Journal:  J Biol Chem       Date:  1987-09-15       Impact factor: 5.157

2.  HER-2/neu oncogene protein and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; A Ullrich; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

3.  Novel fucolipids of human adenocarcinoma: characterization of the major Ley antigen of human adenocarcinoma as trifucosylnonaosyl Ley glycolipid (III3FucV3FucVI2FucnLc6).

Authors:  E Nudelman; S B Levery; T Kaizu; S Hakomori
Journal:  J Biol Chem       Date:  1986-08-25       Impact factor: 5.157

4.  Establishment of an estrogen receptor-positive cell line (HMA-1) derived from human breast carcinoma.

Authors:  S Matano; N Ohuchi; H Hirakawa; T Nishihira; M Abe; S Mori; M Akimoto
Journal:  Tohoku J Exp Med       Date:  1991-06       Impact factor: 1.848

5.  A novel tumor-associated, developmentally regulated glycolipid antigen defined by monoclonal antibody ACFH-18.

Authors:  E D Nudelman; S B Levery; M R Stroud; M E Salyan; K Abe; S Hakomori
Journal:  J Biol Chem       Date:  1988-09-25       Impact factor: 5.157

6.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Authors:  L W Engel; N A Young; T S Tralka; M E Lippman; S J O'Brien; M J Joyce
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

7.  Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope.

Authors:  T Kjeldsen; H Clausen; S Hirohashi; T Ogawa; H Iijima; S Hakomori
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

8.  Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22.

Authors:  G A Croghan; L D Papsidero; L A Valenzuela; T Nemoto; R Penetrante; T M Chu
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

9.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.

Authors:  R Muraro; M Kuroki; D Wunderlich; D J Poole; D Colcher; A Thor; J W Greiner; J F Simpson; A Molinolo; P Noguchi
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

10.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  1 in total

Review 1.  The Cosmc connection to the Tn antigen in cancer.

Authors:  Tongzhong Ju; Rajindra P Aryal; Matthew R Kudelka; Yingchun Wang; Richard D Cummings
Journal:  Cancer Biomark       Date:  2014-01-01       Impact factor: 4.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.